Hydroxychloroquine reduced

ApprovedSmall molecule

UUniversity of Sao Paulo General Hospital

Hydroxychloroquine reduced is one of 39 small molecule programs targeting Autoimmune Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune DiseaseActive, not recruiting

Autoimmune DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Autoimmune Disease

#DrugCompanyPhaseTrials

Myfortic

Novartis

Phase 3

1 2

Remicade

OOrganon and Co

Phase 3

2 3

Atgam

Novartis

Phase 2

2 4

Blincyto

Amgen

Phase 2

1 5

Cytosar

Teva

Phase 2

1 6

Soliris

Rayos

2 8

Alkeran

AApotex Inc.

Phase 2

1 9

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 2

1 10

Vepesid

AAvyxa

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Autoimmune Disease1 trial

Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases

Completed·UUniversity of Sao Paulo General Hospital·Phase 4·NCT03122431·93 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hydroxychloroquine reduced. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hydroxychloroquine reduced compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hydroxychloroquine reduced. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Sao Paulo General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Sao Paulo General Hospital

Hydroxychloroquine reduced

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Autoimmune Disease1 trial

References

Drug Info

Quick Facts

Related News